TPD & Induced Proximity Summit Leaderboard
  • Saturday, June 20, 2026
  • About
  • Advertise
  • Subscribe
  • Contact

Pharma Journalist Pharma Journalist -

Oligonucleotides Analytical Development & CMC Summit Leaderboard
  • Home
  • News
  • Drug Research
  • Clinical Trials
  • Manufacturing
  • Information Technology
  • Packaging & Labeling
  • Diseases
  • Resources
    • Articles
    • Projects
    • Case Studies
    • Industry Reports
    • Interviews
    • White Papers
  • Events
  • Press Releases
Pharma Journalist
  • Home
  • Pharma Journalist
  • Page 31

Author

Pharma Journalist 8887 posts 0 comments

Repertoire, Lilly Team Up on Tolerizing Autoimmune Therapies

Jan 30, 2026
Repertoire® Immune Medicines, a biotechnology company focused on programmable T cell–targeted immune medicines, has entered into a major strategic collaboration with Eli Lilly and…
Read More...

EMA Panel Backs Rezurock for Hard-to-Treat Chronic GVHD

Jan 30, 2026
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending conditional marketing authorisation for Rezurock…
Read More...

FDA Grants Priority Review to Otsuka’s Novel ADHD Drug

Jan 29, 2026
Otsuka Pharmaceutical Development & Commercialization, Inc., together with Otsuka Pharmaceutical Co., Ltd., has reached a key regulatory milestone after the U.S. Food and Drug…
Read More...

Simcere, Boehringer Partner on Bispecific Antibody for IBD Treatment

Jan 28, 2026
Simcere Pharmaceutical Group Ltd. and Boehringer Ingelheim have entered into a global license and collaboration agreement to develop SIM0709, a pre-clinical bispecific antibody designed…
Read More...

Insilico and Qilu Forge AI-Driven Cardiometabolic Drug Partnership

Jan 28, 2026
Insilico Medicine and Qilu Pharmaceutical Group have entered into a strategic partnership aimed at accelerating the discovery and development of new therapies for cardiometabolic…
Read More...

Mirum Completes Bluejay Acquisition, Expands Rare Liver Disease Pipeline

Jan 28, 2026
Mirum Pharmaceuticals, Inc. has completed its acquisition of Bluejay Therapeutics, a privately held biotechnology company focused on viral and liver diseases, marking a significant step…
Read More...

FDA Reviews Weekly Subcutaneous Dosing Option for Eisai’s Alzheimer’s Drug

Jan 28, 2026
Eisai Co., Ltd. and Biogen Inc. have announced a key regulatory milestone for their Alzheimer’s disease therapy lecanemab-irmb, marketed in the United States as LEQEMBI®. The U.S. Food…
Read More...

WuXi Biologics and HanchorBio Partner on Next-Generation Fusion Therapies

Jan 27, 2026
WuXi Biologics and HanchorBio Inc. have announced a strategic collaboration aimed at accelerating the development and manufacturing of multiple next-generation bi- and multi-functional…
Read More...

Corxel Raises $287 Million to Advance Cardiometabolic Drug Pipeline

Jan 26, 2026
Corxel Pharmaceuticals Limited (CORXEL), a clinical-stage biopharmaceutical company focused on cardiometabolic diseases, has announced the successful completion of its Series D1…
Read More...

Janux and Bristol Myers Squibb Forge Global Oncology Collaboration

Jan 23, 2026
Janux Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on next-generation immunotherapies, has entered into a collaboration and exclusive worldwide license…
Read More...
Prev Next
mRNA Process Development & CMC Summit 2026
TPD & Induced Proximity Summit
Measuring Patient Engagement Summit Europe
Oligonucleotides Analytical Development & CMC Summit
11th CAR-TCR Summit
COPD Drug Development Summit
2nd Operationalize: Expanded Access Programs Summit West
Neuropsychiatric Drug Development Summit
International Neoantigen Summit
Lab Ops & Facility Management for Biopharma West Summit
10th IPF Summit
Medical Device Software Development Summit
Liquid Biopsy for Precision Oncology Summit East Coast
ADC Linker & Conjugation Summit
7th Genome Editing Therapeutics Summit
16th World Clinical Biomarkers & Companion Diagnostics Summit
Lipid Nanoparticles Development Summit Europe
iPSC Drug Development Summit
17th World ADC San Diego
Oligonucleotides for CNS Summit
In Vivo Cell Engineering & Gene Editing Summit
Obesity & Weight Loss Drug Development Summit
T-Cell Engager Therapeutics Summit
mRNA-Based Therapeutics Summit
About Us

Pharma Journalist

Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry.

Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry.

Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.

Recent Posts
  • Voro and Alloy Partner on Safer Cancer Immunotherapies
  • uniQure Reports Early Promise for Epilepsy Gene Therapy
  • Boltz and Takeda Expand AI-Powered Drug Discovery Efforts
  • SK Pharmteco Partners With OTXL for Rare Disease Therapies
  • Next-Generation GLP-1 Therapies Are Reshaping the Future of Obesity Treatment

Industry Reports

Amgen Acquires Dark Blue to Advance Novel AML Treatments

Takeda Expands Entyvio Options Through Halozyme Technology…

Inductive Bio Wins $21M to Build AI Drug Toxicity Models

Alkermes Boosts Offer to Acquire Avadel in Deal Worth Up to…

Novartis Completes Acquisition of Tourmaline Bio to…

Press Releases

Advancing Respiratory Medicine Following ATS – What Now?

World ADC San Diego Unveils Preliminary Agenda for 17th…

Regeneron Goes All In on Radiopharma with $2.1B Telix Deal…

IQ MPS Leaders to Share Industry Progress on Advancing In…

4th ADC Linker & Conjugation Summit Announces 2026…

  • About
  • Advertise
  • Subscribe
  • Contact
© 2026 - Pharma Journalist. All Rights Reserved.
Pharma Journalist is a product of
Sign in

Welcome, Login to your account.

Forget password?
Sign in

Recover your password.

A password will be e-mailed to you.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.